Jun 12, 2017




Clinical Hub,Tools & Resources,UWHC Lab Test Directory,Molecular Diagnostics

EBV Qualitative by PCR, Tissue

EBV Qualitative by PCR, Tissue (HCEBVT) Molecular Diagnostics Lab Test

Name: EBV Qualitative by PCR, Tissue

Test Name: EBV Qualitative by PCR, Tissue

Health Link Test Code: HCEBVT

LIS Test Code: EBVT

CPT Code(s): 87798

Methodology: Real-Time PCR

Clinical Information:

Detect EBV in tissue.

Days Performed: Mon-Fri.

In-Lab Turnaround Time: 2 - 3 days.

Stat In-Lab Turnaround Time: Not available stat.

Specimen: Lung, liver, kidney, esophageal, or rectal biopsies

Collection Container: UTM(Universal Transport Medium)

Collection Instructions:

Obtain Universal Transport Medium (UTM) or M4 Culture Transport medium from UWHC Central Service. Place tissue in UTM or M4 Culture Transport medium. Do not freeze tissue in medium.

Collection Volume: 0.1 - 0.2 g

Pediatric Collection Volume: 0.1 - 0.2 g

Stability Ambient:

3 days

Stability Refridgerated:

3 days

Stability Frozen:

Not acceptable

Specimen Transport:

Transport to Laboratory within 2 hours of collection.

Interpretation Type: Expected Results

Additional Information:

False negative results may be due to the suppression of viral replication to levels below the detetion threshold, insufficient specimen collection, or to inhibitory substances that may be present in the specimen. Inadequate specimen collection, processing and storage may invalidate test results. This test should not be used as the only criterion to form a clinical conclusion; instead, results should be correlated with other test results, patient symptoms and clinical presentation. DNA sequence polymorphisms in EBV strains may result in underestimation of viral levels. The presence of variations in EBV DNA sequences are monitored in the real-time PCR assay. This assay does not genotype the virus and consequently does not provide any information regarding EBV drug resistance.


The performance characteristics of this test were validated by UWHC Clinical Laboratories. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. The UWHC Clinical Laboratories is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.